A Randomized Multicenter Study for Isolated Skin Vasculitis



Status:Recruiting
Conditions:Cardiology, Hematology
Therapuetic Areas:Cardiology / Vascular Diseases, Hematology
Healthy:No
Age Range:18 - Any
Updated:2/14/2019
Start Date:January 2017
End Date:December 2019
Contact:Carol McAlear, MA
Email:cmcalear@upenn.edu

Use our guide to learn which trials are right for you!

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of
three different standard of care treatment options for patients with isolated skin
vasculitis.

Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications
under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day)
for 6 months. Endpoint is response to treatment at month 6 (stage 1).

If the patient has to discontinue the study drug within the 6 month study period or during
the subsequent follow-up period (up to month 12) because of a lack of response (or failure),
flare or side effect, he/she will be randomized again to receive one of the remaining two
study drugs (stage 2, with a 1:1 randomization ratio) for 6 months. Endpoint in this second
stage will again be the response to treatment at 6 months.

Inclusion Criteria:

1. Patients with primary skin vasculitis, not associated with any significant
extra-cutaneous involvement that would require specific immunosuppressive therapy.
Eligible patients will have a diagnosis of either:

- Isolated cutaneous small vessel (SV) or medium-sized vessel (MV) vasculitis or
cutaneous polyarteritis nodosa (PAN)

- IgA vasculitis (IgA, formerly Henoch-Schönlein purpura), without active and/or
progressing renal involvement (stable glomerular filtration rate (GFR) >60
ml/min; absence of, or mild-and-stable microscopic hematuria without red blood
cell casts; absence of, or mild-and-stable proteinuria (<1g/24 hours); not
requiring systemic immunosuppressive therapy).

These conditions, when skin-limited, are all currently treated in similar manners in
practice. Mild arthralgias, myalgias, peripheral limb edema, fatigue, weight loss ≤6
lbs or 3 kg within past 3 months, low-grade fever, and mild anemia (Hb ≥ 10 g/dL) will
be allowed.

2. The diagnosis of vasculitis must have been confirmed by skin biopsy prior to
enrollment (earlier, at diagnosis, and/or just prior to enrollment) that has included
an immunofluorescence study (in the case of small vessel vasculitis).

3. Patients must have active cutaneous vasculitis lasting for at least 1 month
continuously and/or have had 2 or more flares over the six months preceding enrollment
(post-inflammatory lesions such as hyperpigmentation or healing ulceration(s) are not
to be considered active vasculitis).

4. Patients must have active / ongoing cutaneous vasculitis lesions at the time of
enrollment (post-inflammatory lesions such as hyperpigmentation or healing
ulceration(s) are not to be considered active vasculitis).

5. Patients may have a contra-indication to one of the study drug or have been treated
prior to enrollment with one of the study medications but failed to respond to it
(according to the study definitions of failure and if they have been on the drug at
the target dose or higher for 3 months or longer) or had to stop it because of an
adverse event. Such patients can be enrolled directly in the second stage of the study
and be randomized to receive one of the two other study drugs. The number of such
patients enrolled directly in stage 2 will be capped at 10 (10% of the total
recruitment target).

6. Patients may have received systemic glucocorticoids for their cutaneous vasculitis
before enrollment. For the patients on prednisone at the time of enrollment,
prednisone should be stopped within a maximum of 6 weeks after enrollment and
initiation of the study drug, following a pre-defined tapering schedule. Patients on
long-term, low and stable dose of glucocorticoids (≤5 mg/day prednisone-equivalent)
for other conditions (e.g., asthma or adrenal insufficiency) can be enrolled if the
likelihood of requiring a dose increase for this other condition is low during the 6
month study period (these patients will remain on that low and stable dose during the
study period, with the option to receive one short course of prednisone at higher
doses for skin vasculitis flare during the first 3 months of the study period, like
any other patients enrolled).

7. Participant age 18 years or greater.

Exclusion Criteria:

1. Presence of significant extra-cutaneous manifestations suggestive of a systemic
vasculitis or more diffuse condition. The presence of mild arthralgias, myalgias,
peripheral limb edema, fatigue, weight loss ≤6 lbs or 3 kg within past 3 months,
low-grade fever, and mild anemia [Hb ≥ 10 g/dL] are not exclusion criteria. Mild and
stable microscopic hematuria without RBC casts and/or mild and stable proteinuria
(<1g/24 hours) are not exclusion criteria. These latter patients must not require
systemic immunosuppressive therapy because of possible renal involvement and their GFR
must be >60 ml/min.

2. Known systemic and/or non-skin-isolated vasculitis, such as granulomatosis with
polyangiitis, eosinophilic granulomatosis with polyangiitis, cryoglobulinemic
vasculitis, systemic polyarteritis nodosa, central nervous system vasculitis and
patients with detectable antineutrophil cytoplasmic antibody (ANCA) by
immunofluorescence or ELISA.

3. Hypocomplementemic urticarial vasculitis, cryoglobulinemic vasculitis, and other known
secondary skin vasculitides such as those secondary to systemic lupus erythematosus,
Sjögren syndrome, another auto-immune condition, a cancer, a hematological disorder,
an ongoing active infection, or an ongoing medication. Investigators should consider
such underlying diagnoses and perform and interpret appropriate laboratory work-up
where indicated based on clinical presentation.

4. History of significant intolerance, allergy or serious adverse events to any of the
study medications: such patients can be enrolled directly in the second stage of the
study and be randomized to receive one of the two other study drugs. The number of
patients enrolled directly in stage 2 of the study will be capped at 10 (10%).

5. Patients who have contra-indications to two or three of the study drugs (azathioprine,
colchicine, or dapsone), or have been treated prior to enrollment with two or three of
the study drugs but failed to respond to them, or had to stop two or three of them
because of adverse events.

6. Deficit in glucose-6-phosphate dehydrogenase (G6PD) or history of hemolytic anemia
(all patients must be tested for G6PD at the screening visit to assess for their
eligibility): such patients can be enrolled directly in the second stage of the study
and be randomized to receive one of the two other study drugs (azathioprine or
colchicine). The number of patients enrolled directly in stage 2 of the study will be
capped at 10 (10%).

7. Low or absent thiopurine methyltransferase (TPMT) activity (if known, not a
requirement for study entry): Patients known to have low or absent TPMT can be
enrolled directly in the second stage of the study and be randomized to receive one of
the two other study drugs (dapsone or colchicine).

8. Evidence of significant hepatic insufficiency or liver function tests > 2 times the
upper limit of normal.

9. Evidence of significant renal insufficiency or creatinine clearance < 60 mL/min.

10. Evidence of significant or symptomatic anemia or Hb < 10 g/dL.

11. Comorbid condition that has moderate or high likelihood of requiring intermittent
courses of prednisone within the study period, according to the investigator (e.g.
chronic obstructive pulmonary disease (COPD), unstable or severe asthma).

12. Active cancer or history of malignancy within the previous 5 years (patient in
remission of a cancer >5 years, or with non-metastatic prostate cancer or treated
basal or squamous cell carcinoma of the skin can be enrolled).

13. Active uncontrolled or serious infection that may compromise or contra-indicate the
use of the study medications.

14. Patient unable to consent.

15. Pregnant or lactating women.
We found this trial at
10
sites
72 East Concord Street
Boston, Massachusetts 02118
(617) 638-5300
Boston University School of Medicine A leader in medical education and research, Boston University School...
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hamilton, Ontario
?
mi
from
Hamilton,
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Lake Success, New York 11042
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
535 E 70th St
New York, New York 10021
(212) 606-1000
Hospital for Special Surgery Founded in 1863, Hospital for Special Surgery is the nation
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials